Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-11 5:28 pm Unchanged |
2021-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Vivo Ventures VI LLC | 1,383,179 5.700% |
0 (Unchanged) |
Filing History |
| 2022-02-11 5:23 pm Sale |
2021-12-31 | 13D | Eiger BioPharmaceuticals, Inc. EIGR |
Vivo Ventures VI LLC | 139 13.000% |
-55,431 (-99.75%) |
Filing History |
| 2022-02-11 5:20 pm Unchanged |
2021-12-31 | 13G | Verona Pharma plc VRNA |
Vivo Ventures VI LLC | 23,493,716 4.900% |
0 (Unchanged) |
Filing History |
| 2021-08-06 4:30 pm Sale |
2021-08-05 | 13D | Eiger BioPharmaceuticals, Inc. EIGR |
Vivo Ventures VI LLC | 55,570 4.910% |
-4,000 (-6.71%) |
Filing History |
| 2021-02-12 4:30 pm Unchanged |
2020-12-31 | 13D | Eiger BioPharmaceuticals, Inc. EIGR |
Vivo Ventures VI LLC | 59,570 5.500% |
0 (Unchanged) |
Filing History |
| 2021-02-12 4:30 pm Purchase |
2020-12-31 | 13G | KalVista Pharmaceuticals, Inc. KALV |
Vivo Ventures VI LLC | 1,383,179 5.900% |
360,686 (+35.28%) |
Filing History |
| 2020-07-24 4:30 pm Purchase |
2020-07-22 | 13G | Verona Pharma plc VRNA |
Vivo Ventures VI LLC | 23,493,716 5.700% |
12,444,448 (+112.63%) |
Filing History |